Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise

Nusinersen: Can SMA Progression Be Stopped?

January 1, 2018 by Mobility Management

The late 2016 introduction of nusinersen (brand name: Spinraza) as a drug therapy for spinal muscular atrophy (SMA) in the United States poses the question: Can SMA be rendered a chronic rather than a progressive condition?

Missy Ball, MT, PT, ATP, said clinical studies of nusinersen used by children and adults have been promising.

“The findings show support for treatment for all types of SMA (especially types 1, 2 and 3) and support early initiation of treatment,” she said. “Results from different studies show improvement in motor function, including ability to sit unassisted, stand or walk when [study participants] would otherwise be unexpected to do so. Also, longevity improved in a greater percentage of patients on Spinraza.”

A November 2017 study published in the New England Journal of Medicine said 51 percent of infants with SMA who were given nusinersen achieved motor-milestone responses, compared to 0 percent of the infants in the control group who didn’t receive nusinersen. The survival rate was also higher in the group that received nusinersen. Researchers suggested that early treatment might be required to fully benefit from the drug’s abilities.

Related Articles Read More >

Briefly: Survey Seeks Input on Rear Anti-Tips; Bryan Anderson Honored with Statue
Featuring Dalhousie University and the La Verne Veterans Memorial.
Collaboration Between Freedom Designs, Motion Concepts to Streamline Provision Process
Invacare America announces a new workflow between two of its divisions.
Kalogon Launches Bondar 3D-Printed Custom Backrest
The new back complements the company’s Orbiter Med wheelchair seat cushion.
Motion Composites Celebrates Opening of New York Assembly Facility
The new facility will start with the assembly of select ultralightweight wheelchair models.

GET THE FREE NEWSLETTER

Mobility Management Newsletter

Subscribe to Mobility Management's newsletter for industry & product news, trends and resources. Click here.
podcasts
Mobility Management
  • HME Business
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • Contact Us
  • About Us

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise